April 2 (Reuters) - Intelligent Bio Solutions Inc INBS.O:
INTELLIGENT BIO SOLUTIONS COMPLETES CLINICAL CUT-OFF STUDY, ADVANCES FDA 510(K) CLINICAL PROGRAM TARGETING MULTI-BILLION-DOLLAR U.S. DRUG SCREENING MARKET
INTELLIGENT BIO SOLUTIONS INC: NOW INITIATED SECOND PHASE OF ITS CLINICAL STUDY PROGRAM
INTELLIGENT BIO SOLUTIONS INC: EXPECTS TO COMPLETE METHOD COMPARISON AND USABILITY STUDY BY END OF JUNE 2026
INTELLIGENT BIO SOLUTIONS INC: COMPLETION OF INTERFERENCE STUDY IS ANTICIPATED BY END OF JULY 2026